Shurong Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shurong Hou has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Xiabin Chen
School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China
11 shared publications Xingyu Deng
School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China
8 shared publicationsYun Zhang
School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China
5 shared publicationsZhenzhen Li
School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China
5 shared publicationsFengling Liu
School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, Zhejiang, China
4 shared publications- Jianzhuang Yao
School of Biological Science and Technology, University of Jinan, Jinan 250022, China
4 shared publications
Latest Publications
- 16 April 2026
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 433, 112088
Substrate specificity and in vivo efficacy of engineered cocaine esterases toward cocaine and its toxic metabolites
- 16 April 2026
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 433, 112088
Substrate specificity and in vivo efficacy of engineered cocaine esterases toward cocaine and its toxic metabolites
- 14 March 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 174, 109756
Design, synthesis, and biological evaluation of novel hydrophobic tag-based degraders targeting JNK1
- 14 March 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 174, 109756
Design, synthesis, and biological evaluation of novel hydrophobic tag-based degraders targeting JNK1
- Open Access
- 13 February 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (2) , 298
Leucine Aminopeptidase from Xanthomonas oryzae pv. oryzae with Esterase Activity Toward Heroin: Biochemical and Catalytic Insights
Heroin is a highly addictive drug that exerts its primary effects through activation of μ-opioid receptors. Its principal active metabolite, 6-monoacetylmorphine (6-MAM), significantly contributes to heroin’s neurological effects and acute toxicity. Current pharmacotherapies for heroin use disorder, employing opioid receptor agonist or antagonist, are often limited by risks of dependence, tolerance, and/or adverse side effects. In this context, enzyme-based therapy emerges as a promising alternative by rapidly converting drugs into inactive or less harmful metabolites in the blood. As a macromolecule, the enzyme does not cross the blood–brain barrier, thereby avoiding side effects in CNS. Through structure-based computational screening, Xoo-PepA (PDB ID: 3JRU), a leucine aminopeptidase from Xanthomonas oryzae pv. oryzae, was identified as a potential enzyme capable of hydrolyzing heroin and 6-MAM. Computational and experimental analyses confirm that Xoo-PepA hydrolyzes heroin sequentially to 6-MAM and subsequently to morphine. Enzymatic properties including dependence on metal ions, optimal pH, thermal stability, and substrate specificity were characterized accordingly. Notably, supplementation with Ni2+ or Zn2+ and TCEP extended Xoo-PepA’s half-life at 37 °C from 1 h to over 24 h, highlighting the essential role of metal ions in maintaining structural stability. Moreover, Ni2+ enhanced Xoo-PepA’s hydrolysis toward peptidase substrate L-leucine-p-nitroaniline by 770-fold, yet conferred no significant activation toward heroin. Mutations in metal ion-coordination residues (e.g., K262A, D267A/E346L) exhibited different activity profiles toward these two types of substrates, suggesting a distinct regulatory mechanism of metal ions may be involved in these activities. This study provides the first demonstration that Xoo-PepA, a non-mammalian, metal-dependent aminopeptidase, can hydrolyze heroin and 6-MAM, shedding light on its functional versatility and biochemical characteristics.
- 13 February 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (2) , 298
Open AccessLeucine Aminopeptidase from Xanthomonas oryzae pv. oryzae with Esterase Activity Toward Heroin: Biochemical and Catalytic Insights
Heroin is a highly addictive drug that exerts its primary effects through activation of μ-opioid receptors. Its principal active metabolite, 6-monoacetylmorphine (6-MAM), significantly contributes to heroin’s neurological effects and acute toxicity. Current pharmacotherapies for heroin use disorder, employing opioid receptor agonist or antagonist, are often limited by risks of dependence, tolerance, and/or adverse side effects. In this context, enzyme-based therapy emerges as a promising alternative by rapidly converting drugs into inactive or less harmful metabolites in the blood. As a macromolecule, the enzyme does not cross the blood–brain barrier, thereby avoiding side effects in CNS. Through structure-based computational screening, Xoo-PepA (PDB ID: 3JRU), a leucine aminopeptidase from Xanthomonas oryzae pv. oryzae, was identified as a potential enzyme capable of hydrolyzing heroin and 6-MAM. Computational and experimental analyses confirm that Xoo-PepA hydrolyzes heroin sequentially to 6-MAM and subsequently to morphine. Enzymatic properties including dependence on metal ions, optimal pH, thermal stability, and substrate specificity were characterized accordingly. Notably, supplementation with Ni2+ or Zn2+ and TCEP extended Xoo-PepA’s half-life at 37 °C from 1 h to over 24 h, highlighting the essential role of metal ions in maintaining structural stability. Moreover, Ni2+ enhanced Xoo-PepA’s hydrolysis toward peptidase substrate L-leucine-p-nitroaniline by 770-fold, yet conferred no significant activation toward heroin. Mutations in metal ion-coordination residues (e.g., K262A, D267A/E346L) exhibited different activity profiles toward these two types of substrates, suggesting a distinct regulatory mechanism of metal ions may be involved in these activities. This study provides the first demonstration that Xoo-PepA, a non-mammalian, metal-dependent aminopeptidase, can hydrolyze heroin and 6-MAM, shedding light on its functional versatility and biochemical characteristics.
- Open Access
- 5 June 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (6) , 822
Biochemical and Functional Characterization of E. coli Aminopeptidase N: A New Role as a 6-Monoacetylmorphine Hydrolase
6-monoacetylmorphine (6-MAM), a primary active metabolite of heroin that reaches the human brain, plays a crucial role in producing heroin-associated physiological and lethal effects. Therefore, 6-MAM has emerged as a key target for alleviating the adverse consequences of heroin abuse. In this study, the proposed 6-MAM hydrolase E. coli aminopeptidase N (eAPN) was recombinantly produced, and its biochemical and functional profiles were investigated. eAPN’s biochemical properties, with respect to pH, metal ions, and temperature, and catalytic functions toward peptidase substrates and 6-MAM were thoroughly examined. Extensive experiments reveal that incorporation of an N-terminal His-tag notably affects eAPN’s aminopeptidase activity. This cost-effective recombinant eAPN exhibits favorable thermostability and optimal activity at pH 7.5. Kinetic analysis toward peptidase substrates reveals that eAPN preferentially cleaves peptides following amino acid residues in the order of Ala > Arg >> Met, Gly > Leu > Pro, indicating a preference for small or basic amino acid residues as substrates. Computational and experimental studies have, for the first time, discovered that eAPN is capable of catalyzing the hydrolysis of heroin and 6-MAM, which has shed light on its functional versatility and potential applications. This work elucidates the biochemical properties of eAPN and expands its catalytic functions, thereby laying the groundwork for a deep understanding and further reengineering of eAPN to enhance its activity toward 6-MAM for heroin detoxification.
- 5 June 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (6) , 822
Open AccessBiochemical and Functional Characterization of E. coli Aminopeptidase N: A New Role as a 6-Monoacetylmorphine Hydrolase
6-monoacetylmorphine (6-MAM), a primary active metabolite of heroin that reaches the human brain, plays a crucial role in producing heroin-associated physiological and lethal effects. Therefore, 6-MAM has emerged as a key target for alleviating the adverse consequences of heroin abuse. In this study, the proposed 6-MAM hydrolase E. coli aminopeptidase N (eAPN) was recombinantly produced, and its biochemical and functional profiles were investigated. eAPN’s biochemical properties, with respect to pH, metal ions, and temperature, and catalytic functions toward peptidase substrates and 6-MAM were thoroughly examined. Extensive experiments reveal that incorporation of an N-terminal His-tag notably affects eAPN’s aminopeptidase activity. This cost-effective recombinant eAPN exhibits favorable thermostability and optimal activity at pH 7.5. Kinetic analysis toward peptidase substrates reveals that eAPN preferentially cleaves peptides following amino acid residues in the order of Ala > Arg >> Met, Gly > Leu > Pro, indicating a preference for small or basic amino acid residues as substrates. Computational and experimental studies have, for the first time, discovered that eAPN is capable of catalyzing the hydrolysis of heroin and 6-MAM, which has shed light on its functional versatility and potential applications. This work elucidates the biochemical properties of eAPN and expands its catalytic functions, thereby laying the groundwork for a deep understanding and further reengineering of eAPN to enhance its activity toward 6-MAM for heroin detoxification.
- 15 December 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 154, 108044
Design and synthesis of JNK1-targeted PROTACs and research on the activity
- 15 December 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 154, 108044
Design and synthesis of JNK1-targeted PROTACs and research on the activity
- 26 November 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 116, 130044
Discovery of a selective and potent inhibitor of c-Jun N-terminal kinase 1 with anti-pulmonary fibrosis effect
- 26 November 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 116, 130044
Discovery of a selective and potent inhibitor of c-Jun N-terminal kinase 1 with anti-pulmonary fibrosis effect
- 17 November 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 283 (Pt 3) , 137767
Catalytic mechanism, computational design, and crystal structure of a highly specific and efficient benzoylecgonine hydrolase
- 17 November 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 283 (Pt 3) , 137767
Catalytic mechanism, computational design, and crystal structure of a highly specific and efficient benzoylecgonine hydrolase
- 9 July 2024
- Published by Wiley in Protein Science
- Vol. 33 (8) , e5098
Discovery of a novel homocysteine thiolactone hydrolase and the catalytic activity of its natural variants
Homocysteine thiolactone (HTL), a toxic metabolite of homocysteine (Hcy) in hyperhomocysteinemia (HHcy), is known to modify protein structure and function, leading to protein damage through formation of N‐Hcy‐protein. HTL has been highly linked to HHcy‐associated cardiovascular and neurodegenerative diseases. The protective role of HTL hydrolases against HTL‐associated vascular toxicity and neurotoxicity have been reported. Although several endogeneous enzymes capable of hydrolyzing HTL have been identified, the primary enzyme responsible for its metabolism remains unclear. In this study, three human carboxylesterases were screened to explore new HTL hydrolase and human carboxylesterase 1 (hCES1) demonstrates the highest catalytic activity against HTL. Given the abundance of hCES1 in the liver and the clinical significance of its single‐nucleotide polymorphisms (SNPs), six common hCES1 nonsynonymous coding SNP (nsSNPs) variants were examined and characterized for their kinetic parameters. Variants E220G and G143E displayed 7.3‐fold and 13.2‐fold lower catalytic activities than its wild‐type counterpart. In addition, the detailed catalytic mechanism of hCES1 for HTL hydrolysis was computational investigated and elucidated by Quantum mechanics/molecular mechanics (QM/MM) molecular dynamics (MD) method. The function of residues E220 and G143 in sustaining its hydrolytic activity of hCES1 was analyzed, and the calculated energy difference aligns well with experimental‐derived results, supporting the validity of our computational insights. These findings provide insights into the potential protective role of hCES1 against HTL‐associated toxicity, and warrant future studies on the possible association between specific genetic variants of hCES1 with impaired catalytic function and clinical susceptibility of HTL‐associated cardiovascular and neurodegenerative diseases.
- 9 July 2024
- Published by Wiley in Protein Science
- Vol. 33 (8) , e5098
Discovery of a novel homocysteine thiolactone hydrolase and the catalytic activity of its natural variants
Homocysteine thiolactone (HTL), a toxic metabolite of homocysteine (Hcy) in hyperhomocysteinemia (HHcy), is known to modify protein structure and function, leading to protein damage through formation of N‐Hcy‐protein. HTL has been highly linked to HHcy‐associated cardiovascular and neurodegenerative diseases. The protective role of HTL hydrolases against HTL‐associated vascular toxicity and neurotoxicity have been reported. Although several endogeneous enzymes capable of hydrolyzing HTL have been identified, the primary enzyme responsible for its metabolism remains unclear. In this study, three human carboxylesterases were screened to explore new HTL hydrolase and human carboxylesterase 1 (hCES1) demonstrates the highest catalytic activity against HTL. Given the abundance of hCES1 in the liver and the clinical significance of its single‐nucleotide polymorphisms (SNPs), six common hCES1 nonsynonymous coding SNP (nsSNPs) variants were examined and characterized for their kinetic parameters. Variants E220G and G143E displayed 7.3‐fold and 13.2‐fold lower catalytic activities than its wild‐type counterpart. In addition, the detailed catalytic mechanism of hCES1 for HTL hydrolysis was computational investigated and elucidated by Quantum mechanics/molecular mechanics (QM/MM) molecular dynamics (MD) method. The function of residues E220 and G143 in sustaining its hydrolytic activity of hCES1 was analyzed, and the calculated energy difference aligns well with experimental‐derived results, supporting the validity of our computational insights. These findings provide insights into the potential protective role of hCES1 against HTL‐associated toxicity, and warrant future studies on the possible association between specific genetic variants of hCES1 with impaired catalytic function and clinical susceptibility of HTL‐associated cardiovascular and neurodegenerative diseases.